TruZen® Health has announced the results of a first ever human-based clinical trial, proving its proprietary TruZen® CBD formula with patented VESIsorb® Technology achieves 360% greater bioavailability of β-caryophyllene (BCP).
PITTSBURGH, Nov. 30, 2022 /PRNewswire-PRWeb/ -- Nutraceuticals Innovator TruZen® Health has announced the results of a first ever human-based clinical trial, proving its proprietary TruZen® CBD formula with patented VESIsorb® Technology achieves 360% greater bioavailability of β-caryophyllene (BCP).
BCP is a natural bicyclic sesquiterpene and a common constituent of the essential oils of numerous food plants such as hemp (Cannabis sativa L) and is thought to interact with the endocannabinoid system by binding selectively to cannabinoid receptors type 2 (CB2). Decades of preclinical research have investigated the potential therapeutic benefits of BCP, such as analgesic, anti-inflammatory, and anti-depressive.
The clinical trial, a randomized, double-blind, cross-over design, single oral dose study1 [100 mg β-caryophyllene (BCP)] in 24 healthy subjects (12 men/12 women) was performed under fasted conditions and evaluated the relative bioavailability of BCP formulated with VESIsorb® to that of the same BCP neat oil. In addition to the superior PK results of the BCP VESIsorb® formulation, there are significant findings that highlight the scientific and medical contributions from this new study.
- This is the first published study to demonstrate safe and well-tolerated BCP doses as high as 100 mg, a 10x increase compared to the natural daily human exposure
- This is the first published study to demonstrate that BCP has poor bioavailability in humans
- This is the first published study to reveal there is no significant difference between men and women for both investigated formulations and all investigated PK endpoints
The new clinical trial was conducted by Geocann®, a global cannabis organization that combines clinically researched cannabinoids and terpenes with technologically advanced drug delivery system technologies that increase absorption and bioavailability for maximum health benefits.
Reference more on the new human clinical trial here: https://www.mdpi.com/1420-3049/27/9/2860
Widely regarded as today's best-in-class CBD product produced under the highest ethical and quality standards, TruZen® has also been validated as a superior CBD product in a previously published Clinical Trial Study: "A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects."
Unlike typical CBD products, TruZen® CBD delivers a lipid-based, natural, hemp oil product to be delivered in a water-soluble form with no loss in bio-efficacy or absorption. Its patented VESIsorb® delivery system has been proven in previously conducted human clinical trials to increase absorption by mor than 400 times other CBD products. TruZen® CBD softgels disperse uniformly, transferring the CBD bioactives directly to the intestinal lymphatic system for boosted bioavailability and faster results. Benefits start in 90 seconds, and users will feel the full effect within 30 to 60 minutes. TruZen® CBD is 4.4 times more bioavailable than the leading CBD brand made with MCT oil. Tests show that the human body needs only 25 mg of TruZen® CBD to their 100 mg.
According to TruZen® Health VP Operations and Co-Founder, Michael Lioon, "we are very excited by the results of this first ever human-based clinical trial, validating our proprietary TruZen® formula with VESIsorb®'s superior potency and absorbency of β-caryophyllene (BCP). Our commitment to providing the highest quality, clinically proven products is stronger than ever today."
TruZen® CBD is manufactured by TruZen® Health, continuing its legacy of three family generations and 70 years of nutraceutical experience, with products produced under the highest ethical standards. TruZen® CBD is the first product it has ever offered directly to consumers.
TruZen® Health is offering all new customers an introductory 10-Day trial of TruZen® CBD. To learn more, please visit https://www.truzenhealth.com/10-day-trial-special/.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. **EpiCor® is a registered trademark of Embria Health Sciences,
###
Media Contact
Douglas Lioon Jr., TruZen® Health, 1 412-338-3831, [email protected]
SOURCE TruZen® Health
Share this article